Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ADC Therapeutics SA (ADCT)

ADC Therapeutics Q3 net product revenue rises to $21.0 million; net loss narrows

Positive Impact 3 of 5 earnings

ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.

Key points

  • Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
  • Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
  • Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
  • October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.

The filing

CompanyADC Therapeutics SA (ADCT)
Form8-K, current report
Filed with the SECNov 9, 2026, 8:06 AM ET
Accession number0001628280-26-071899

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:31 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.